Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group trial GOG-0199

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages 3275-3283

  Sherman, Mark E ^a   Piedmonte, Marion ^e   Mai, Phuong L ^a   Ioffe, Olga B ^b   Ronnett, Brigitte M ^c   Van Le, Linda ^h   Ivanov, Iouri ⁱ   Bell, Maria C ^j   Blank, Stephanie V ^f   Disilvestro, Paul ^k   Hamilton, Chad A ^d   Tewari, Krishnansu S ^l   Wakeley, Katie ^m   Kauff, Noah D ^g   Yamada, S Diane ^o   Rodriguez, Gustavo ^p   Skates, Steven J ⁿ   Alberts, David S ^q   Walker, Joan L ^r   Minasian, Lori ^a   Lu, Karen ^s   Greene, Mark H ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ Pathology Department   (United States)

^j UNIVERSITY OF SOUTH DAKOTA   (United States)

^k WOMEN AND INFANTS HOSPITAL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m TUFTS UNIVERSITY   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o UNIVERSITY OF CHICAGO   (United States)

^p NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^q UNIVERSITY OF ARIZONA   (United States)

^r UNIVERSITY OF OKLAHOMA   (United States)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TUMOR ANTIGEN; CA 125 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER SURGERY; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PREVALENCE; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; TUMOR INVASION; BLOOD; BREAST TUMOR; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL TRIAL; FALLOPIAN TUBE NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; MULTICENTER STUDY; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; CA-125 ANTIGEN; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907484183     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.1987     Document Type: Article

References (71)

1. Rebbeck TR, Kauff ND, Domchek SM: Metaanalysis of risk reduction estimates associated with riskreducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87, 2009
2. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
3. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010
4. Cibula D, Zikan M, Dusek L, et al: Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: A meta-analysis. Expert Rev Anticancer Ther 11:1197-1207, 2011
5. Beral V, Doll R, Hermon C, et al: Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 371:303-314, 2008
6. Iodice S, Barile M, Rotmensz N, et al: Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. Eur J Cancer 46:2275-2284, 2010
7. Cibula D, Widschwendter M, Majek O, et al: Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum Reprod Update 17:55-67, 2011
8. Buys SS, Partridge E, Black A, et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305:2295-2303, 2011
9. Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327-340, 2009
10. Rosenthal AN, Fraser L, Manchanda R, et al: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 31:49-57, 2013
11. McCarthy AM, Menke A, Ouyang P, et al: Bilateral oophorectomy, body mass index, and mortality in U. S. women aged 40 years and older. Cancer Prev Res (Phila) 5:847-854, 2012
12. Parker WH, Broder MS, Chang E, et al: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 113:1027-1037, 2009
13. Rocca WA, Grossardt BR, de Andrade M, et al: Survival patterns after oophorectomy in premenopausal women: A population-based cohort study. Lancet Oncol 7:821-828, 2006
14. Kurman RJ, Shih IeM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: Shifting the paradigm. Hum Pathol 42:918-931, 2011
15. Crum CP, McKeon FD, Xian W: The oviduct and ovarian cancer: Causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol 55:24-35, 2012
16. Piek JM, van Diest PJ, Zweemer RP, et al: Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451-456, 2001
17. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 9:1191-1197, 2008
18. Sherman ME, Guido R, Wentzensen N, et al: New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research. Gynecol Oncol 127:645-650, 2012
19. Przybycin CG, Kurman RJ, Ronnett BM, et al: Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34:1407-1416, 2010
20. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol 204:19.e1-19.e6, 2011
21. Kotsopoulos IC, Tsapanos VS: Patient groups that fimbriectomy could reduce high grade serous ovarian cancer incidence. Gynecol Oncol 128:151-152, 2013
22. Westgren M: Prevention of ovarian cancer: Let's do something. Acta Obstet Gynecol Scand 9:1009-1010, 2012
23. Leblanc E, Narducci F, Farre I, et al: Radical fimbriectomy: A reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes?Rationale and preliminary development. Gynecol Oncol 121:472-476, 2011
24. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
25. Colgan TJ, Murphy J, Cole DE, et al: Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283-1289, 2001
26. Carcangiu ML, Peissel B, Pasini B, et al: Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: Report of 6 cases and review of the literature. Am J Surg Pathol 30:1222-1230, 2006
27. Powell CB, Kenley E, Chen LM, et al: Riskreducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127-132, 2005
28. Finch A, Shaw P, Rosen B, et al: Clinical and pathologic findings of prophylactic salpingooophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100:58-64, 2006
29. Leeper K, Garcia R, Swisher E, et al: Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87:52-56, 2002
30. Leunen K, Legius E, Moerman P, et al: Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: Importance of fallopian tube dysplasia. Int J Gynecol Cancer 16:183-188, 2006
31. Hirst JE, Gard GB, McIllroy K, et al: High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 19:826-829, 2009
32. Laki F, Kirova YM, This P, et al: Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109:1784-1790, 2007
33. Evans DG, Clayton R, Donnai P, et al: Riskreducing surgery for ovarian cancer: Outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 17:1381-1385, 2009
34. Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 194:1702-1709, 2006
35. Lu KH, Garber JE, Cramer DW, et al: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728-2732, 2000
36. Callahan MJ, Crum CP, Medeiros F, et al: Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25:3985-3990, 2007
37. Olivier RI, van Beurden M, Lubsen MA, et al: Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90:1492-1497, 2004
38. Hermsen BB, van Diest PJ, Berkhof J, et al: Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 119:1412-1418, 2006
39. Bacha OM, Gregoire J, Grondin K, et al: Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer 22:974-978, 2012
40. Reitsma W, de Bock GH, Oosterwijk JC, et al: Support of the "fallopian tube hypothesis" in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 49:132-141, 2013
41. Yates MS, Meyer LA, Deavers MT, et al: Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: Building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 4:463-470, 2011
42. Salazar H, Godwin AK, Daly MB, et al: Microscopic benign and invasive malignant neoplasms and a cancerprone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820, 1996
43. Eltabbakh GH, Piver MS, Hempling RE, et al: Laparoscopic management of women with a family history of ovarian cancer. J Surg Oncol 72:9-13, 1999
44. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002
45. Finch A, Beiner M, Lubinski J, et al: Salpingooophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185-192, 2006
46. Vicus D, Finch A, Cass I, et al: Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol 118:299-302, 2010
47. Domchek SM, Friebel TM, Garber JE, et al: Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat 124:195-203, 2010
48. Manchanda R, Abdelraheim A, Johnson M, et al: Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 118:814-824, 2011
49. Powell CB, Chen LM, McLennan J, et al: Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: Experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 21:846-851, 2011
50. Rabban JT, Mackey A, Powell CB, et al: Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: Implications for intraoperative specimen evaluation. Gynecol Oncol 121:466-471, 2011
51. Rhiem K, Foth D, Wappenschmidt B, et al: Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283:623-627, 2011
52. Meeuwissen PA, Seynaeve C, Brekelmans CT, et al: Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97:476-482, 2005
53. Jóhannsson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
54. Deligdisch L, Gil J, Kerner H, et al: Ovarian dysplasia in prophylactic oophorectomy specimens: Cytogenetic and morphometric correlations. Cancer 86:1544-1550, 1999
55. Finch AP, Lubinski J, Møller P, et al: Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1531-1533, 2014
56. Greene MH, Piedmonte M, Alberts D, et al: A prospective study of risk-reducing salpingooophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics-A Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 17:594-604, 2008
57. Skates SJ: Ovarian cancer screening: Development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 22:S24-S26, 2012 (suppl 1)
58. Skates SJ, Mai P, Horick NK, et al: Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) 4:1401-1408, 2011
59. Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, et al: Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 25:1383-1389, 2007
60. Bolton KL, Chenevix-Trench G, Goh C, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382-390, 2012
61. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333, 2007
62. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian (version 1.2014). www.nccn.org
63. Rabban JT, Krasik E, Chen LM, et al: Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: Implications for defining an optimal specimen dissection protocol. Am J Surg Pathol 33:1878-1885, 2009
64. Medeiros F, Muto MG, Lee Y, et al: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230-236, 2006
65. Nicosia SV, Wilbanks GD, Saunders B, et al: Cytology of human ovarian surface epithelial brushings. Cancer 102:1-10, 2004
66. Rungruang B, Hood BL, Sun M, et al: Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome. J Proteome Res 9:6071-6076, 2010
67. Domchek SM, Gaudet MM, Stopfer JE, et al: Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 119:409-414, 2010
68. Lavie O, Ben-Arie A, Segev Y, et al: BRCA germline mutations in women with uterine serous carcinoma: Still a debate. Int J Gynecol Cancer 20:1531-1534, 2010
69. Brinton LA, Felix AS, McMeekin DS, et al: Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 129:277-284, 2013
70. Pennington KP, Walsh T, Lee M, et al: BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 119:332-338, 2013
71. Jarboe EA, Miron A, Carlson JW, et al: Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: Frequency and potential significance. Int J Gynecol Pathol 28:308-315, 2009